MedTrace Logo

Immunogenicity of Quadrivalent Meningococcal Conjugate Vaccine in Frequent Platelets Donors

NCT04224311 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2022-11-15

No results posted yet for this study

Summary

In this study, the investigators will evaluate the immunogenicity of a quadrivalent conjugate meningococcal vaccine in healthy, plateletpheresis donors.

Conditions

  • Preventive Immunization; Meningitis

Interventions

BIOLOGICAL

Menactra

0.5 mL dosage of Menactra will be administered by intramuscular injection in the deltoid muscle on day 0.

Sponsors & Collaborators

  • Brigham and Women's Hospital

    lead OTHER

Principal Investigators

  • Lindsey Baden, MD · Brigham and Women's Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-03-12
Primary Completion
2023-10-01
Completion
2024-04-15
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04224311 on ClinicalTrials.gov